Latest: Cohance Life Q1 FY27 results →All Q2 FY26 results →

CL

Cohance Life

Q2 FY26

Cohance Life Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹464

Market cap₹17.8K Cr

P/E164.9

Updated16 Oct 2026

Read4 min read

The short version

Cohance Lifesciences aims to achieve a US$1 billion revenue milestone by 2030. Cohance Lifesciences aims to achieve a US$1 billion revenue milestone by 2030, indicating strong long-term growth expectations.

From Cohance Life's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Cohance Lifesciences aims to achieve a US$1 billion revenue milestone by 2030.
The growth strategy includes both organic expansion and aggressive inorganic growth through M&A.
Focus will be on becoming a key global CDMO (Contract Development and Manufacturing Organization) player with niche technologies.
Expansion includes existing modalities like ADC (Antibody-Drug Conjugates) and oligonucleotide capabilities and selectively acquiring differentiated, profitable assets.
The company is working on robust RFP pipelines and has secured large customer orders, including Phase 3 commercialization products.
New leadership hires are focused on accelerating growth and execution efficiency.

2 more points from Cohance Life's call on revenue

Create a free account to keep reading this call

Profitability & Margins

Cohance Lifesciences aims to achieve a US$1 billion revenue milestone by 2030, indicating strong long-term growth expectations.
The company continues to focus on tech-driven businesses, particularly in CDMO, ADC, and oligonucleotide capabilities, to drive profitable growth.
Management is committed to cost optimization through Lean Six Sigma and aggressive cost targets, aiming to manage short-term cost impacts from organizational changes.
Inorganic growth via M&A is a strategic priority, with a focus on acquiring differentiated, profitable assets that add unique capabilities.
The company plans to fund growth primarily through internal resources, maintaining a cash-positive position by the end of the strategic period.

2 more points from Cohance Life's call on margins

Create a free account to keep reading this call

See what Cohance Life said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Surya oligonucleotide unit has completed equipment validation and is on track for commissioning in Q4, expanding advanced therapy capabilities.
SuryaPet facility is scheduled to be capitalized in line with a confirmed Phase 3 order from a large Japanese customer, supporting commercial scale execution.
The company is proactively addressing remediation at the Nacharam FTF unit with guidance from leading U.S. and Indian consulting firms.
Strategic inorganic growth is a key priority, with an in-house M&A team actively scouting for differentiated, profitable assets with niche capabilities aligned to the $1 billion vision.

2 more points from Cohance Life's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

Cohance Lifesciences plans to fund growth opportunities primarily through internal funding.
If required, the company may consider borrowing, but the current focus is on minimizing debt.
The company aims to remain cash positive throughout its strategic growth period.
The capital structure is aligned to support internal funding and reduce reliance on external borrowing.

2 more points from Cohance Life's call on fundraising

Create a free account to keep reading this call

See what Cohance Life said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Recently completed four major customer orders across CDMO facilities successfully.
RFP pipeline is becoming more robust with addition of BD team and commercial investments.
A large Japanese customer has confirmed its Phase 3 order, a key milestone for CDMO business.
SuryaPet facility is scheduled for capitalization aligned with this confirmed order.
Multiple mid-phase projects actively under discussion with a large innovator customer, whose leadership team is expected to visit soon.

2 more points from Cohance Life's call on order book

Create a free account to keep reading this call

Cohance Life — Quarterly revenue & net profit

Revenue Net profit

Dec 2024Q3 FY25

Mar 2025Q4 FY25

Jun 2025Q1 FY26

Sep 2025Q2 FY26

Dec 2025Q3 FY26

Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹619 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Cohance Lifesciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Cohance Life and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Cohance Life Q2 FY26 results?

Cohance Lifesciences aims to achieve a US$1 billion revenue milestone by 2030. Cohance Lifesciences aims to achieve a US$1 billion revenue milestone by 2030, indicating strong long-term growth expectations.

What is Cohance Life share price analysis?

Cohance Life currently shows a neutral. The stock trades at a P/E of 164.9 with a market cap of ₹17,754 Cr. Investors should review the full earnings analysis for detailed insights.

Is Cohance Life planning capital expenditure?

Surya oligonucleotide unit has completed equipment validation and is on track for commissioning in Q4, expanding advanced therapy capabilities. - SuryaPet facility is scheduled to be capitalized in line with a confirmed Phase 3 order from a large Japanese customer, supporting commercial scale execution. - The company is proactively addressing remediation at the Nacharam FTF unit with guidance from leading U.S.

Keep Cohance Life on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.